Xenova P-gp Inhibitor Enters Phase I for Multi-Drug Resistance In Cancer
Executive Summary
Xenova's P-glycoprotein pump inhibitor XR9576 has entered Phase I trials for P-gp-related multi-drug resistance in cancer, the firm announced May 12.
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS032211
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS032211
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.